钾竞争性酸阻断剂治疗酸相关疾病的研究进展  

Recent advances in the treatment of acid related diseases with potassium competitive acid blockers

作　　者：王萍[1] 刘亚婷 赵莹[1] 李新[1] WANG Ping;LIU Ya-ting;ZHAO Ying(Pharmacy Department of Tianjin Beichen Hospital,Tianjin 300400,China)

机构地区：[1]天津市北辰医院药剂科,天津300400

出　　处：《中国处方药》2023年第5期170-176,共7页Journal of China Prescription Drug

基　　金：天津市北辰区卫健系统科技项目(SHGY-2020033)。

摘　　要：钾竞争性酸阻断剂(potassium-competitive acid blockers,P-CABs)是一类新型抑酸药物,通过竞争性地阻断胃H+/K+-ATP酶的钾离子结合位点进而产生抑制胃酸分泌的作用。代表药物有伏诺拉生、替戈拉生、瑞普拉生等。P-CABs目前已成为酸相关性疾病治疗领域的研究热点。经大量临床研究证实,与传统抑酸剂相比,P-CABs在治疗胃食管反流病、嗜酸性食管炎、幽门螺杆菌感染、内镜下黏膜下剥离术后人工溃疡和迟发性出血以及消化性溃疡等方面具有起效快、抑酸作用更强和更持久、安全性良好的优点。Potassium-competitive acid blockers(P-CABs)are a new class of acid inhibitors,which can inhibit gastric acid secretion by competitively blocking the potassium ion binding site of gastric H+/K+-ATPase.The representative drugs are vonoprazan,tegoprazan,and revaprazan.P-CABs have become a research hotspot in the treatment of acid related diseases.A large number of clinical studies have confirmed that,compared with traditional acid inhibitors,P-CABs have the advantages of rapid onset,stronger and more lasting acid inhibition and safety in the treatment of gastroesophageal reflux disease,eosinophilic esophagitis,helicobacter pylori infection,artificial ulcer and delayed bleeding after endoscopic submucosal dissection,and peptic ulcer.

关 键 词：钾离子竞争性酸阻滞剂 伏诺拉生 酸相关疾病 

分 类 号：R57[医药卫生—消化系统]